| pubmed-article:18701231 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18701231 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:18701231 | lifeskim:mentions | umls-concept:C0025663 | lld:lifeskim |
| pubmed-article:18701231 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:18701231 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:18701231 | lifeskim:mentions | umls-concept:C1516048 | lld:lifeskim |
| pubmed-article:18701231 | lifeskim:mentions | umls-concept:C1872431 | lld:lifeskim |
| pubmed-article:18701231 | lifeskim:mentions | umls-concept:C0332324 | lld:lifeskim |
| pubmed-article:18701231 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:18701231 | pubmed:dateCreated | 2008-10-20 | lld:pubmed |
| pubmed-article:18701231 | pubmed:abstractText | A sensitive liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method was developed to investigate isosteviol pharmacokinetics in vivo. Isosteviol was extracted from plasma with hexane and 4% formic acid. A Phenomenex Synergi 2mu Fusion reversed phase analytical HPLC column (50 mm x 2.0 mm) equipped with a Synergi 2micro Fusion guard column was employed for chromatographic separations. The gradient mobile phase consisted of acetonitrile (ACN) and 20mM ammonium acetate at pH 6.5, starting at 20% ACN and ramping to 80% at 7 min, followed by 80% ACN for 1 min, then 20% ACN for 5 min. Negative SRM was used to monitor the m/z 317.1/317.1 and 317.3/317.3 transitions for isosteviol and 395.0/395.0 and 397.0/397.0 transitions for internal standard. The retention time of isosteviol was 9.2 min. The assay was linear over the range of 50-2,000 ng/mL. The accuracy of the method was in the range of 97-105%. Intra- and inter-day precisions were in the range of 1.5-4.6%. Isosteviol (4 mg/kg) was dosed intravenously and orally to Sprague-Dawley rats (n=6). Plasma samples were collected and analysed. Intravenous isosteviol has a distribution half-life of 35.7+/-9.0 min with the initial distribution volume of 68.1+/-9.4 mL. The total clearance, terminal half-life and steady-state volume of distribution were 1.25+/-0.12 mL/min, 150.6+/-50.5 min and 272.6+/-95.9 mL, respectively. The oral bioavailability of isosteviol was found to be 60.4+/-15.5%. | lld:pubmed |
| pubmed-article:18701231 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18701231 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18701231 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18701231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18701231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18701231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18701231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18701231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18701231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18701231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18701231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18701231 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18701231 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:18701231 | pubmed:issn | 0731-7085 | lld:pubmed |
| pubmed-article:18701231 | pubmed:author | pubmed-author:LOOAA | lld:pubmed |
| pubmed-article:18701231 | pubmed:author | pubmed-author:WangJipingJ | lld:pubmed |
| pubmed-article:18701231 | pubmed:author | pubmed-author:DaveyAndrew... | lld:pubmed |
| pubmed-article:18701231 | pubmed:author | pubmed-author:JinHongpingH | lld:pubmed |
| pubmed-article:18701231 | pubmed:author | pubmed-author:GerberJacobus... | lld:pubmed |
| pubmed-article:18701231 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18701231 | pubmed:day | 4 | lld:pubmed |
| pubmed-article:18701231 | pubmed:volume | 48 | lld:pubmed |
| pubmed-article:18701231 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18701231 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18701231 | pubmed:pagination | 986-90 | lld:pubmed |
| pubmed-article:18701231 | pubmed:meshHeading | pubmed-meshheading:18701231... | lld:pubmed |
| pubmed-article:18701231 | pubmed:meshHeading | pubmed-meshheading:18701231... | lld:pubmed |
| pubmed-article:18701231 | pubmed:meshHeading | pubmed-meshheading:18701231... | lld:pubmed |
| pubmed-article:18701231 | pubmed:meshHeading | pubmed-meshheading:18701231... | lld:pubmed |
| pubmed-article:18701231 | pubmed:meshHeading | pubmed-meshheading:18701231... | lld:pubmed |
| pubmed-article:18701231 | pubmed:meshHeading | pubmed-meshheading:18701231... | lld:pubmed |
| pubmed-article:18701231 | pubmed:meshHeading | pubmed-meshheading:18701231... | lld:pubmed |
| pubmed-article:18701231 | pubmed:meshHeading | pubmed-meshheading:18701231... | lld:pubmed |
| pubmed-article:18701231 | pubmed:meshHeading | pubmed-meshheading:18701231... | lld:pubmed |
| pubmed-article:18701231 | pubmed:meshHeading | pubmed-meshheading:18701231... | lld:pubmed |
| pubmed-article:18701231 | pubmed:meshHeading | pubmed-meshheading:18701231... | lld:pubmed |
| pubmed-article:18701231 | pubmed:meshHeading | pubmed-meshheading:18701231... | lld:pubmed |
| pubmed-article:18701231 | pubmed:meshHeading | pubmed-meshheading:18701231... | lld:pubmed |
| pubmed-article:18701231 | pubmed:meshHeading | pubmed-meshheading:18701231... | lld:pubmed |
| pubmed-article:18701231 | pubmed:meshHeading | pubmed-meshheading:18701231... | lld:pubmed |
| pubmed-article:18701231 | pubmed:meshHeading | pubmed-meshheading:18701231... | lld:pubmed |
| pubmed-article:18701231 | pubmed:meshHeading | pubmed-meshheading:18701231... | lld:pubmed |
| pubmed-article:18701231 | pubmed:meshHeading | pubmed-meshheading:18701231... | lld:pubmed |
| pubmed-article:18701231 | pubmed:meshHeading | pubmed-meshheading:18701231... | lld:pubmed |
| pubmed-article:18701231 | pubmed:meshHeading | pubmed-meshheading:18701231... | lld:pubmed |
| pubmed-article:18701231 | pubmed:meshHeading | pubmed-meshheading:18701231... | lld:pubmed |
| pubmed-article:18701231 | pubmed:meshHeading | pubmed-meshheading:18701231... | lld:pubmed |
| pubmed-article:18701231 | pubmed:meshHeading | pubmed-meshheading:18701231... | lld:pubmed |
| pubmed-article:18701231 | pubmed:meshHeading | pubmed-meshheading:18701231... | lld:pubmed |
| pubmed-article:18701231 | pubmed:meshHeading | pubmed-meshheading:18701231... | lld:pubmed |
| pubmed-article:18701231 | pubmed:meshHeading | pubmed-meshheading:18701231... | lld:pubmed |
| pubmed-article:18701231 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18701231 | pubmed:articleTitle | Oral and i.v. pharmacokinetics of isosteviol in rats as assessed by a new sensitive LC-MS/MS method. | lld:pubmed |
| pubmed-article:18701231 | pubmed:affiliation | Sansom Institute, City East, School of Pharmacy and Medical Science, University of South Australia, Adelaide, SA 5000, Australia. | lld:pubmed |
| pubmed-article:18701231 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18701231 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
